Last reviewed · How we verify
Tramadol Hydrochloride; JNS013
At a glance
| Generic name | Tramadol Hydrochloride; JNS013 |
|---|---|
| Sponsor | Janssen Pharmaceutical K.K. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain (PHASE3)
- A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain (PHASE3)
- An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain (PHASE3)
- An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tramadol Hydrochloride; JNS013 CI brief — competitive landscape report
- Tramadol Hydrochloride; JNS013 updates RSS · CI watch RSS
- Janssen Pharmaceutical K.K. portfolio CI